Category Archives: Global News Feed

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will provide an end-of-year business update on veverimer’s development program, regulatory status and patent protection.

Read this article:
Tricida to Provide an End-of-Year Business Update

TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma as an independent member of the company’s board of directors. Ms. Thoma is a seasoned pharmaceutical industry executive with more than 30 years of experience spanning product development and commercialization, as well as operations and supply chain management.

Continued here:
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors

– Treatment with Mitapivat Induced Hemoglobin Increase of ?1.0 g/dL in 6 of 11 (55%) Efficacy Evaluable Patients, Decreased Markers of Hemolysis, Reduced 2,3-DPG and Increased ATP –

The rest is here:
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.

Visit link:
Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.

See the article here:
electroCore to Present at the 13th Annual LD Micro Main Event Conference

Pompano Beach, Fl., Oct. 27, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced the launch of AEON™, the 6th and newest addition to the Company’s perinatal tissue allograft platform.

See the article here:
BioStem Technologies, Inc. Announces Launch of AEON™

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chief Scientific Officer, Dr. Kenneth Cundy, will participate on the panel titled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus” at the ROTH Capital COVID-19 Therapeutics in Development Event, being held virtually on October 28, 2020 at 7:30am PT. A live webcast of the presentation will be available for attendees who register at https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ.

See the rest here:
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will be presenting a poster during the 29th European Academy of Dermatology and Venereology (EADV) Congress being held virtually October 28 – November 1, 2020. The presentation will be posted onto Akari’s website.

See the original post here:
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress...

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX?CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix?M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) meeting.

More here:
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company’s American Depositary Receipts (“ADRs”).

Go here to see the original:
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)